These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 18799288)

  • 1. Once-weekly D-cycloserine effects on negative symptoms and cognition in schizophrenia: an exploratory study.
    Goff DC; Cather C; Gottlieb JD; Evins AE; Walsh J; Raeke L; Otto MW; Schoenfeld D; Green MF
    Schizophr Res; 2008 Dec; 106(2-3):320-7. PubMed ID: 18799288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments.
    Buchanan RW; Javitt DC; Marder SR; Schooler NR; Gold JM; McMahon RP; Heresco-Levy U; Carpenter WT
    Am J Psychiatry; 2007 Oct; 164(10):1593-602. PubMed ID: 17898352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia.
    Goff DC; Tsai G; Levitt J; Amico E; Manoach D; Schoenfeld DA; Hayden DL; McCarley R; Coyle JT
    Arch Gen Psychiatry; 1999 Jan; 56(1):21-7. PubMed ID: 9892252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. d-Cycloserine augmentation of cognitive remediation in schizophrenia.
    Cain CK; McCue M; Bello I; Creedon T; Tang DI; Laska E; Goff DC
    Schizophr Res; 2014 Mar; 153(1-3):177-83. PubMed ID: 24485587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. D-cycloserine added to clozapine for patients with schizophrenia.
    Goff DC; Tsai G; Manoach DS; Flood J; Darby DG; Coyle JT
    Am J Psychiatry; 1996 Dec; 153(12):1628-30. PubMed ID: 8942463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia.
    Goff DC; Tsai G; Manoach DS; Coyle JT
    Am J Psychiatry; 1995 Aug; 152(8):1213-5. PubMed ID: 7625475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Placebo-controlled trial of glycine added to clozapine in schizophrenia.
    Evins AE; Fitzgerald SM; Wine L; Rosselli R; Goff DC
    Am J Psychiatry; 2000 May; 157(5):826-8. PubMed ID: 10784481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia.
    Goff DC; Lamberti JS; Leon AC; Green MF; Miller AL; Patel J; Manschreck T; Freudenreich O; Johnson SA
    Neuropsychopharmacology; 2008 Feb; 33(3):465-72. PubMed ID: 17487227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of D-cycloserine on negative symptoms in schizophrenia.
    Duncan EJ; Szilagyi S; Schwartz MP; Bugarski-Kirola D; Kunzova A; Negi S; Stephanides M; Efferen TR; Angrist B; Peselow E; Corwin J; Gonzenbach S; Rotrosen JP
    Schizophr Res; 2004 Dec; 71(2-3):239-48. PubMed ID: 15474895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. D-cycloserine adjuvant therapy to molindone in the treatment of schizophrenia.
    Rosse RB; Fay-McCarthy M; Kendrick K; Davis RE; Deutsch SI
    Clin Neuropharmacol; 1996 Oct; 19(5):444-50. PubMed ID: 8889288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A placebo-controlled crossover trial of D-cycloserine added to clozapine in patients with schizophrenia.
    Goff DC; Henderson DC; Evins AE; Amico E
    Biol Psychiatry; 1999 Feb; 45(4):512-4. PubMed ID: 10071726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. D-Cycloserine added to risperidone in patients with primary negative symptoms of schizophrenia.
    Evins AE; Amico E; Posever TA; Toker R; Goff DC
    Schizophr Res; 2002 Jul; 56(1-2):19-23. PubMed ID: 12084415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia.
    Heresco-Levy U; Ermilov M; Shimoni J; Shapira B; Silipo G; Javitt DC
    Am J Psychiatry; 2002 Mar; 159(3):480-2. PubMed ID: 11870017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. D-cycloserine facilitation of cognitive behavioral therapy for delusions in schizophrenia.
    Gottlieb JD; Cather C; Shanahan M; Creedon T; Macklin EA; Goff DC
    Schizophr Res; 2011 Sep; 131(1-3):69-74. PubMed ID: 21723096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. D-cycloserine increases positive symptoms in chronic schizophrenic patients when administered in addition to antipsychotics: a double-blind, parallel, placebo-controlled study.
    van Berckel BN; Evenblij CN; van Loon BJ; Maas MF; van der Geld MA; Wynne HJ; van Ree JM; Kahn RS
    Neuropsychopharmacology; 1999 Aug; 21(2):203-10. PubMed ID: 10432468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multicenter, add-on randomized controlled trial of low-dose d-serine for negative and cognitive symptoms of schizophrenia.
    Weiser M; Heresco-Levy U; Davidson M; Javitt DC; Werbeloff N; Gershon AA; Abramovich Y; Amital D; Doron A; Konas S; Levkovitz Y; Liba D; Teitelbaum A; Mashiach M; Zimmerman Y
    J Clin Psychiatry; 2012 Jun; 73(6):e728-34. PubMed ID: 22795211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study.
    Lane HY; Chang YC; Liu YC; Chiu CC; Tsai GE
    Arch Gen Psychiatry; 2005 Nov; 62(11):1196-204. PubMed ID: 16275807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of risperidone and quetiapine on cognition in patients with schizophrenia and predominantly negative symptoms.
    Riedel M; Spellmann I; Strassnig M; Douhet A; Dehning S; Opgen-Rhein M; Valdevit R; Engel RR; Kleindienst N; Müller N; Möller HJ
    Eur Arch Psychiatry Clin Neurosci; 2007 Sep; 257(6):360-70. PubMed ID: 17629731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine.
    de Lucena D; Fernandes BS; Berk M; Dodd S; Medeiros DW; Pedrini M; Kunz M; Gomes FA; Giglio LF; Lobato MI; Belmonte-de-Abreu PS; Gama CS
    J Clin Psychiatry; 2009 Oct; 70(10):1416-23. PubMed ID: 19906345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose galantamine augmentation inferior to placebo on attention, inhibitory control and working memory performance in nonsmokers with schizophrenia.
    Dyer MA; Freudenreich O; Culhane MA; Pachas GN; Deckersbach T; Murphy E; Goff DC; Evins AE
    Schizophr Res; 2008 Jul; 102(1-3):88-95. PubMed ID: 18325740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.